Harrison.ai vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Harrison.ai is an Australian healthcare AI company building clinical-grade AI for radiology and pathology diagnostics; raised $129M+ AUD total at a $400M AUD valuation; its Annalise.ai radiology platform has FDA clearance and processes 5M+ studies;
About
Harrison.ai is a Sydney, Australia-based healthcare artificial intelligence company founded in 2018 by brothers Aengus and David Hallinan that builds clinical-grade AI models for diagnostic medicine, initially targeting radiology and pathology. The company''s flagship product — Annalise.ai — is a comprehensive AI platform for radiology interpretation that analyzes chest X-rays, CT scans, and other medical imaging studies to detect and flag a broad range of findings simultaneously. Unlike earlier radiology AI tools designed for single conditions, Annalise.ai is a multi-finding model trained to detect up to 124 findings in a single chest X-ray and 295 findings in chest CTs — providing a comprehensive AI second reader experience rather than a narrow single-disease detector.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.